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Infections caused by multidrug resistant organisms 
(MDROs) are severely challenging the healthcare 
systems worldwide.  Resistance to antibacterial drugs 
is growing in both Gram positive and Gram negative 
bacteria and is increasingly related to healthcare as-
sociated infections (HAIs). Undoubtedly, multiresis-
tant Gram-negatives, especially carbapenem-resistant 
Enterobacteriaceae (CRE) and Acinetobacterbau-
mannii, represent the cutting edge of crisis today (1). 
Therapeutic options for these organisms are so ex-
tremely limited that old, previously forgotten drugs, 
such as polymixins, have come back touse in absence 
of robust data guiding dosage regimens or duration of 
treatment. Moreover, panresistant strains have always 
been reported (2).
Antibiotic resistance costs: the Alliance for the Pru-
dent Use of Antibiotics (APUA) (http://www.tufts.
edu/med/apua/) has estimated for United States of 
America alone a cost currently ranging between $24 
billion and $38 billion a year. A report by the Europe-
an Centre for Disease Control (ECDC) (http://www.
ecdc.europa.eu/en/), focusing on four main types of 
infection - bloodstream, lower respiratory tract, skin 
and soft tissue and urinary tract infections -has high-
lighted that resistance is causing annually an eco-
nomic burden of more than 900 million euros of extra 
in-hospitalcosts and about 600 million days of lost 
productivity. In this respect, poorer countries seem to 
be even more disadvantaged. The poorer the country, 
the larger is the proportion of its health-care budget 
being absorbed by the cost of antibacterial drugs: in-
deed, antibacterial drug resistance forces healthcare 
to turn from cheaper, but previously largely adminis-
tered drugs, to more expensive alternatives (3). 
Unfortunately, a synergistic combination of factors, 
including the evolving healthcare delivery policies 
and the shifting of patient demographics and underly-
ing conditions towards higher risk profiles, is deeply 
changing the landscape of HAIs. All countries are 
involved in this global crisis with different weights 
attributable to a variety of concurrent factors. Just to 
name a few, poor healthcare resources, poor quality 
of antibiotics, and sometimes over-the-counter avail-
ability of antibiotics, are likely playing an important 
role in developing countries.  In developed countries, 
financial crisis and cutting resources to healthcare 
systems along with the expanding population of old 
and chronically ill patients, are worsening the situa-
tion. Finally, travels, transfer of patients and the so-
called “medical tourism” are bridging the boundaries 
between the developed and developing countries daily 
(4). Worldwide reports show that MDRO’s infections 
are increasingly serious and are in exorably spilling 
over into the community, mainly through different al-
ternative healthcare settings, such as long-term care 
facilities (LTCFs) (5). Additionally, elderly and im-
munocompromised persons with comorbidities, who 
are recurrently going back and forth between hospi-
tals and LTCFs, contribute to the spread of MDROs 
and likely represent the largest and misunderstood 
reservoir of MDROs within the health care network 
(2, 5).
The second driving force of the crisis is the fall-
ing number of new antibacterial drugs approved for 
marketing: indeed, mainly in the field of the MDR 
Gram negative bacilli, the pharmaceutical industry is 
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failing to deliver new antibacterials to replace those 
made ineffective by resistance. Indeed, along several 
decades,the pharmaceutical industry has funded and 
pursued research and development on antimicrobial 
drugs based on a return on investment in terms of fu-
ture sales. However, in the last years, this business 
model has become unsustainable: the costs of new 
antibacterial development have increased under the 
pressure of heavier regulatory burdens, but the chance 
of success has parallelly declined by making invest-
ment in this field less and less attractive compared 
to other types of longer-lived therapeutic agents, par-
ticularly those prescribed for chronic illness (2, 3).
So, the mainstay of any control measure for re-
ducing MDRO’s infections is the implementation 
of basic precautions based upon understanding of 
how they are transmitted. A popular slogan is “back 
to basics: hand hygiene!” (http://blogs.cdc.gov/
safehealthcare/?p=1646)- very reasonable, but not so 
easily applied. Transmission of MDROs is, indeed, 
influenced by many different and intertwined issues, 
including organizational and institutional factors. 
Growing evidence is accumulating about the effects of 
overcrowding, understaffing and bed occupancy rates 
on the risk of MDRO’s infections. Indeed, several 
studies have described over crowding and understaff-
ing as factors promoting decreased healthcare worker 
hand hygiene adherence and levels of cohorting, over 
burdened isolation facilities and increased movement 
of patients and staff between hospital wards (6, 7). 
All these factors, which have been synthesized with 
the term “organizational fatigue”, are associated with 
higher nurse-patient interaction and cross-infections 
rates (6, 7). So, the healthcare cost containment strat-
egies aimed at obtaining greater efficiency by cut-
ting the number of hospital beds, reducing the staff 
and increasing patient throughput, are likely causing 
negative side effects on patient safety and quality of 
healthcare, putting at risk the efforts to control and 
prevent MDRO’s infections. This stress on the health-
care systems may, indeed, actually increase hospital 
costs due to rise in HAIs as a consequence of lapses in 
infection control practices by over burdened health-
care workers, as previously observed in some report-
ed outbreaks (6-8). Moreover, wide spread diffusion 
of MDROs may result in ward closures and these, in 
turn, in delayed elective admissions and over crowd-
ing of related wards and emergency units, triggering 
vicious cycles where hygienic practices are unable to 
prevent new infections.
Successful prevention or interruption of epidemic 
MDROs have been achieved in both epidemic and 
non epidemic settings, by implementing rigorous 
measures at the local or, sometime, regional or na-
tional level (5). Evidence is sufficiently solid that 
following implementation of strict control measures, 
such as screening of new admissions in high-risk 
wards and isolation/cohorting of colonized and in-
fected patients, incidence of MDRO’s infections has 
stabilized or declined (5). To find smart approaches is 
imperative, but translating the huge quantity of white 
and gray literature into practice needs knowledge of 
local epidemiology which can be substantially dif-
ferent from place to place. According to the World 
Health Organization (WHO), surveillance system de-
ficiency amplifies antibacterial drug resistance (http://
www.who.int/drugresistance/about/en/index.html). 
International collaborative efforts would be required 
to enable accurate and continuous monitoring of the 
global spread of antibiotic-resistant bacteria. How-
ever, in developed countries, many studies have been 
carried out, but through limited times and in single 
facilities or small, poorly representative samples of 
hospitals. Even worse, reliable data from vast areas 
of Africa and Asia are scarce or absent. Effective sur-
veillance systems aimed to obtain basic information 
to customize prevention and control interventions 
are essential and are not be considered an extra-cost. 
Similarly, the role and skill of the microbiology labo-
ratories in detecting and typing MDROs are critical 
for infection prevention and control (5). Moreover, 
proponents of changes to healthcare systems towards 
a higher efficiency should learn to give more attention 
to adverse events, such as spread of MDRO’s infec-
tions and consequent declining quality of care and as-
sociated costs.
Last, but not least, a more judicious policy of an-
tibiotics use is urgently needed to be adopted on a 
worldwide scale. Unfortunately, there are no easy and 
universal answers to the question of how to prevent 
excessive and inappropriate use of antibiotics. How-
ever, all opportunities are to be promoted to learn 
from each other’s experience on how to control an-
tibiotic use through restriction policies, educational 
interventionsad dressing the issues of inappropriate 
prescription and unnecessary self-medication, and 
improving technologies to accurately and timely di-
agnose bacterial infections. Restriction of over-the-
counter dispensing of antimicrobials without a pre-
scription and regulation of the manufacture of drugs 
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to assure their purity and potency are also urgent in 
all countries. Mean while, antibiotic over-use around 
the world in livestock and fish farming is not to be 
forgotten.
International efforts are also required to encourage 
pharmaceutical companies to develop new antibiotics. 
Recent closer attention to the problem of antimicro-
bial resistance from the WHO and many international 
and national health agencies suggests that urgency of 
the current situation is now better recognized. Some 
global initiatives have also been launched. For in-
stance, the British Society for Antimicrobial Chemo-
therapy (BSAC) has recently established “Antibiotic 
Action” (http://antibiotic-action.com/), which is call-
ing all interested parties – governments, healthcare 
professionals, industry and charities – to identify and 
implement solutions to “regenerate the discovery and 
development of antibacterial drugs”.
The time for action is today according to the WHO, 
to warrant cure for tomorrow. 
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